Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Multidisciplinary mass gathering and celebration of European basic, translational and clinical studies (5/5)

EMCC 2011

23 - 27 Sep 2011

Published: 11 Apr 2011

Views: 4894

Rating:

Save

Michael Baumann - ECCO President & Congress Chair; David Kerr - ESMO President; Anne-Lise Børresen Dale - Scientific Co-Chair (ECCO)

Discussants hand-pick just some of the many reasons why you should register to attend, submit your exciting data, and join us in Stockholm to collectively advance European cancer therapeutics and prevention at the 2011 European Multidisciplinary Cancer Congress, 23 – 27 September.

Categories:
Biomarkers

Related Videos

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )

Avelumab combined with regorafenib shows improved outcome in solid tumours with...

Prof Antoine Italiano - Institute Bergonié, Bordeaux, France

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures ( Prof Antoine Italiano - Institute Bergonié, Bordeaux, France )

Urinary markers in the surveillance setting of non-muscle invasive bladder...

Dr Thomas Dreyer - Aarhus University Hospital, Aarhus, Denmark

Urinary markers in the surveillance setting of non-muscle invasive bladder cancer ( Dr Thomas Dreyer - Aarhus University Hospital, Aarhus, Denmark )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

To test or not to test? Targeted therapies in GU Cancers – leveraging new...

Prof Eva Compérat, Dr Friederike Schlürmann and Dr Guilhem Roubaud

To test or not to test? Targeted therapies in GU Cancers – leveraging new advances in clinical care ( Prof Eva Compérat, Dr Friederike Schlürmann and Dr Guilhem Roubaud )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Remote genetic testing has the potential to increase the uptake of testing in...

Dr Bruce Montgomery - University of Washington, Seattle, USA

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems ( Dr Bruce Montgomery - University of Washington, Seattle, USA )

More from ecancer